Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0022104 (irritable bowel syndrome)
 8,033 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The pathogenic significance of cell adhesion molecules (CAMs) in ulcerative colitis (UC) is largely unknown. Colonic expression of E-selectin, sialyl Lewis X (sLe(x)), and macrophage inflammatory protein-1x (MIP-1alpha) as well as serum concentrations of E-selectin and MIP-1alpha in UC were studied. Thirty patients with UC, 10 patients with irritable bowel syndrome, and 10 healthy subjects were included. Colonic biopsies were stained immunohistochemically, and blood concentrations were measured with an ELISA technique. Soluble E-selectin did not correlate with diagnosis or disease activity. MIP-1alpha was below the detection limit. Epithelial cells expressed all three molecules, both on surface membranes and intracellularly. sLe(x) staining was weaker (P = 0.0002) and MIP-1alpha staining stronger (P = 0.014) in UC patients than in controls. Leukocyte MIP-alpha staining correlated with diagnosis (P = 0.021), sLe(x) staining (P = 0.023), and colonoscopy (P = 0.018). It is shown that E-selectin, sLe(x), and MIP-1alpha are synthesized and expressed by epithelial cells, indicating that CAMs are not only involved in leukocyte extravasation and migration, but also in the interaction between leukocytes and colonic epithelium. This knowledge might contribute to the development of improved treatments in UC.
 ...
PMID:Expression of E-selectin, sialyl Lewis X, and macrophage inflammatory protein-1alpha by colonic epithelial cells in ulcerative colitis. 953 57

One of the key links of pathological inflammatory process is the formation factors of adhesion. They play a leading role in the formation of inflammatory infiltration of the mucosa of the colon. Changes in the levels factors of adhesion under the influence of biological therapy are not well understood. In this regard, the aim of our study was to investigate the influence of biological therapy (infliximab, mesenchymal stromal cells) on the level of adhesion molecules in patients with IBD. Investigated the role of adhesion molecules to evaluate the effectiveness of treatment in this group of patients. Was examined 30 patients with IBD. Of these, 16 patients with ulcerative colitis (UC) and 14 patients with Crohn's disease (CD). Of these, 16 patients received infliximab 5 mg/kg body weight, 14 patients with IBD who underwent a comprehensive anti-inflammatory therapy with the introduction of MSC culture. Before and after treatment with infliximab, MSC transplantation was carried out a study of the clinical blood test, CRP, determined by the level of adhesion molecule L-selectin, E-selectin, P-selectin, integrin - sVCAM-1 in serum by ELISA Under the influence of infliximab for all IBD patients had significantly lower levels of P-selectin, E-selectin, integrin - sVCAM-1. In the group of patients after MSC transplantation rates of P-selectin, E-selectin was significantly decreased and the level of integrin - sVCAM-1 decreased slightly. The level of L-selectin in patients both after MSC transplantation and therapy with infliximab is practically not reduced, which serves as a reflection of chronic autoimmune inflammation, and the basis for long-term use of biological therapy in IBD. Adhesion molecule P-selectin, E-selectin, integrin - sVCAM-1 decreased more rapidly under the influence of infliximab in patients with IBD because of the mechanism of drug action (suppression of the synthesis of core inflammatory cytokine TNF-alpha). After transplantation of MSCs P-selectin, E-selectin, integrin - sVCAM-1 decreased more slowly due to the fact that the maximum positive effect of MSCs developed after 1 month. P-selectin, E-selectin, L-selectin, integrin - sVCAM-1 are the modern markers of inflammation and can be used to evaluate the effectiveness of biological therapy in IBD and the prognosis of the disease.
 ...
PMID:[The role of adhesion molecules for assessing the effectiveness of biological treatment of patients with inflammatory bowel disease]. 2340 83